Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Day (June 2023)

42 slides from Windtree Therapeutics's investor day presentation, Jun 14, 2023

  1. Slide 1: Windtree Therapeutics R&D and Investor Day

    Windtree Therapeutics ‘ R&D and Investor Day June 14, 2023 Se —@ WINDTREE (NASDAQ: WINT)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the ‘Company

  3. Slide 3: Welcome and Agenda

    Welcome Craig Fraser, President &CEO Agenda Steve Simonson, MD * Introduce Windtree John Teerlink, MD * Overview the Cardiogenic Shock Market and Landscape * Introduce Istaroxime and the Rationale for a Cardiogeni¢ Shock Program + SEISMIC Trial and Results * Development Strategy and Plans to Transit

  4. Slide 4: Windtree Therapeutics overview

    q Icy ee ~~ WINDTREE THERAPEUTICS Biopharmaceutical company with advanced clinical focus on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has consistently demonstrate

  5. Slide 5: Pipeline

    Pipeline Lead Products | Indication Istaroxime Cardiogenic Shock Istaroxime Acute Heart Failure OralSERCA2a Chronic Heart Failure, including Activators potentially HFPEF ‘Treatment Resistant Rostafuroxin Hypertension - Genetically Associated KL4surfactant KL4sufactant OrvgDevice Tx for RDS and poten

  6. Slide 6: Istaroxime Cardiogenic Shock

    2 - my Istaroxime Cardiogenic Shock Potential indication in active clinical development

  7. Slide 7: Cardiogenic Shock

    Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and flow to and from the body and vital organs (hypoperfusion) accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency. » Caused by severe impairment of

  8. Slide 8: Market Research: Early Cardiogenic Shock Treatment

    Market Reseai Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need + No satisfactory pharmacological intervention to reverse the conditions ~ Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action @ wees ene Relaxation ‘and subsequent contraction cycle via stimulation of SERCAZa activity which enhances calcium reuptake @ Incr

  10. Slide 10: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials

    Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials Cardiac Function Improved * Significant increase in stroke volume (amount of blood pumped with each heartbeat) + Lowered cardiac filling pressures art Dose-related Increase in Systolic Blood Pressure ~ i te eS Maintain or Inc

  11. Slide 11: SEISMiC Early Cardiogenic Shock Study

    SEISMiC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure @ p 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime.

  12. Slide 12: Difference in SBP Profile

    NE Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population 0, Distaroxime Placebo Change from Baseline in SBP (mmH 8 7 6 5 4 3 1 ° o os 1 is 2 2 3 38 4 45 5 SS 6 Se Hours from Infusion Inititation _ WINDTREE [xe

  13. Slide 13: Secondary Results

    \ Secondary Results — Results Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure ‘mITT Population 20 Pr ~®Istaroxime 3 © Placebo z = & ra a A 6 | p=0.025 for AUC alAbed ° 0 2 24 Hours from Infusion Initiation ve WINDTREE 3)

  14. Slide 14: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: v Cardiac index significantly increased yv Stroke volume substantially increased » (4 mL/m2) approaching statistical significance y Other parameters were also im

  15. Slide 15: Treatment was Associated with a Favorable Renal Profile

    Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate miTT Population a 22 = —E o g = £2 4 resale ' ~. 2a £4 Pec a= 5 ee lair | ie o 6 © Placebo 2 ° 2 24 36 ms eo 7 a % Hours from infusion initiati

  16. Slide 16: Comparison of Doses

    ) Comparison of Doses of Doses 1.0 yg/kg/min Produced a Favorable Effect on SBP 1.0 ug/kgimin dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function » More favorable adverse event, serious adverse event and clinical event pro

  17. Slide 17: SEISMIC Results Summary

    SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) - SBP increases were rapi

  18. Slide 18: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy SEISMIC Extension Study = Extended and titrated dosing for optimization = Additional characterization SEISMIC a” arses see nase 3* Study * Position for EOP2 * Proof of concept > srailes sepreties by SGA! Stake Bde’ to/AUE AHF safety data base, = Learnings about

  19. Slide 19: Plan For Dose Optimization — Extension Study

    Plan For Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associa

  20. Slide 20: Descriptors of SCAI Shock Stages

    Descriptors of SCAI Shock Stages: e> z Basing cS nics WINDTREE

  21. Slide 21: SCAI Stage C Study

    SCAI Stage C Study linatt loll, se a6 WINDTREE Study Objectives: * 20 patients with SCAI Stage C shock due to ADHF: Hypotension + hypoperfusion Protocol will allow additional enrollment after this review Istaroxime or placebo will be added to initial standard of care shock therapy (blinded) * Hold s

  22. Slide 22: Our Development Plan (studying SCAI stage B, C)

    Our Development Plan (studying SCAI stage B, C) Designed To Maximize Cardiogenic Shock Addressable Market % of CS Patients, Experiencing Early to Extreme CS, 2% ‘Very severe and unstable: mechanical intervention 1% —_______+ 30% KS SCAI B, C: Focus for Ista CS Development 86% + SCAICcharacterized by

  23. Slide 23: Cardiogenic Shock Opportunity

    Cardiogenic Shock Opportunity <4 NIN WSN se a6 WINDTREE Average length of stay in U.S. ~19.5 days: >$200k in patient costs OPPORTUNITY DRIVERS Currently available pharmacologictreatments have undesirable side effects and poor outcomes Very high cost of cardiogenicshock treatment creates opportunity

  24. Slide 24: John R. Teerlink, MD

    se a6 WINDTREE John R. Teerlink, MD Harvard Medical School followed by an internal medicine residency at the University of California San Francisco (UCSF). He continued a post-doctoral research fellowship at Hoffman-LaRoche in Basel, Switzerland. Dr. Teerlink completed his cardiovascular medicine fe

  25. Slide 25: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients hospitalization ~1.3M us. Tus. ; in patients ~1.5M cv. 25M +F worawiae > 65 years old >$18B 0 In-patient mortality annual U.S. hospit

  26. Slide 26: Istaroxime AHF Phase 2a & 2b Studies

    Istaroxime AHF Phase 2a & 2b Studies se a6 WINDTREE ZS eh oO Phase 2a n=120 Dosing= 6 hour ADHF Patients 0.5, 1, 1.5 ygikgimin Infusion Phase n=120 Dosing= 24 hour ADHF Patients 0.5, 1.0 uokaimin Infusion 2b (ayspnea plusneed {orlv furosemide 2 40mg) Primary: PCWP significantly improved Stroke Vol &

  27. Slide 27: Istaroxime — Acute Heart Failure

    i Istaroxime — Acute Heart Failure Objective: Evaluate potential Phase 3 AHF program based on data from our cardiogenic shock program Potential Phase 3 AHF Program Augment our data from the positive phase 2a and phase 2b AHF studies ay with the efficacy, safety and dosing and characterization learni

  28. Slide 28: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds * Oral & i.v. therapies for chronic “Next generation istaroxime” as

  29. Slide 29: Active Engagement in Out-License and Partnership Opportunities

    Active Engagement in Out-License and Partnership Opportunities v AEROSURF / KL4 Platform — Exclusive global license to Lee’s Pharm (SEHK:950) and Zhaoke. Potential proceeds: © Up to $78.9 million in potential milestone payments Global / Regional © Low double-digit % royalties Licensing © WINT no lon

  30. Slide 30: Strategy for Value-Creation

    Strategy for Value-Creation - Focus for the Next 4-6 Quarters Clinical Milestones Strong trial Extension and Enable transi Execute sel . WINDTREE Transformative BD THERAPEUTICS ; Licensing and partnership for High IR/PR non-dilutive value Communication Y ‘dedicated media, et opportunities and mitiga

  31. Slide 31: Financial Summary & Capitalization

    Financial Summary & Capitalization Cash March 31, 2023 $4.2M Driving Capital Efficiency to Program Investment Significantly reduced company expenses and cash burn via out- March 31, 2023 Pro Forma $15.0M licensing KL4 platform, focused resources on lead priority program Common Equivalents “ Total Co

  32. Slide 32: Q&A

    Q&A www.Windtreetx.com se a6 WINDTREE

  33. Slide 33: Slide 33

  34. Slide 34: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need Patient Management Goals Current Treatment Options * Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary Heart rhythm disturbance

  35. Slide 35: Cardiogenic Shock Treatment

    Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Regulatory Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Ot _©©— Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of dr

  36. Slide 36: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume Istaroxime 0.5 yg/kg/min vs. placebo *pvalue =0.029 2aheurs ——«@howre Bacaline =-4- Praceto-Cohot 1 ee istzonine oS yyt9me e Infusion period Semine «ham Mhoum—Doum &R nam race - Hesse 0S porgiin Cy WINDTREE Ele’ Stroke Vo

  37. Slide 37: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve e 0.5 g/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo 1 z Gare Be * Brraues £0.006 E Blood == * is a? Pressure 3° ze 4 (SBP) ae i: 4 i: a 5 a Zl insion period eos eon Then Hos Aeon Tatoos Tomine Shoes G

  38. Slide 38: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins se w@ WINDTREE ‘Change in lear tate (om) Istaroxime 0.5 yg/kg/min vs. placebo *pvalue=0.014 == Pieeto-Cohen = tawcine sultan eTnT-0to 24 hours —eo5ugKomn —e—1ougngmn ~~» —Placere Cardiac TnT (Myocardial Damage) ‘ange intent tate opm) Istarox

  39. Slide 39: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring 120% 100% 80% | 60% 40% 20% oo% Clinically Significant Arrhythmias celine sPiaebo- Cohort 25.0% 75% Baeaine stains 05 ugKglmn Placebo -Conot2 20% em 1258 100% 100% 100% | & . | oo L — ay 1 ntusion) Day 2 ‘Day 1 tus) Day 2 ‘mistxcrime 10 ugK9m

  40. Slide 40: Adverse Events

    Adverse Events Pooled placebo _‘"staroxime 0.5 Istaroxime 1.0 (a9) mgi/Kgimin mgiKgimin (0=41) (n=40) All adverse events: 23 (59.0%) 31 (75.6%) 33 (82.5%). eaettgs even lees 126%) : 4(10.0%) Serious adverse events 2 (5.1%) 2(4.9%) 6 (15.0%) Cardiac death - - 1 (2.5%) Cardiogenic shock z z 1 (25%) Ca

  41. Slide 41: Rostafuroxin — A Potential New Treatment for Resistant Hypertension

    Rostafuroxin — A Potential New Treat for Resistant Hypertension (RHTN) Rostafuroxin There have been seven clinical studies of rostafuroxin in treatment naive hypertension (patients without any treatment), including 4 Phase 2 studies which examined the antihypertensive effect, safety and tolerability

  42. Slide 42: Large Market with Significant Unmet Need

    Large Market with Significant Unmet Need » Treatment resistant hypertension — An estimated 10% to 20% of hypertensive patients have resistant hypertension, defined as having controlled or uncontrolled blood pressure with the use of = 3 medications that includes a diuretic* » Effective hypertension t

Windtree Therapeutics — Investor Day (June 2023) on 6ix